MIRA INFORM REPORT

 

 

Report Date :

19.11.2014

 

IDENTIFICATION DETAILS

 

Name :

KOWA COMPANY LTD

 

 

Registered Office :

3-6-29 Nishiki Nakaku Nagoya 460-8625

 

 

Country :

Japan

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

November 1939

 

 

Com. Reg. No.:

1800-01-035811 (Nagoya-Nakaku)

 

 

Legal Form :

Limited Company (Kabushiki Kaisha)

 

 

Line of Business :
  • Mfg of pharmaceuticals, medical equipment;
  • Import, export, wholesale of textiles, apparel, machinery, chemicals, other

 

 

No of Employees :

5,819

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

Yen 4,306.7 million

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 1, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

JAPAN - ECONOMIC OVERVIEW

 

In the years following World War II, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (1% of GDP) helped Japan develop a technologically advanced economy. Two notable characteristics of the post-war economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features are now eroding under the dual pressures of global competition and domestic demographic change. Japan's industrial sector is heavily dependent on imported raw materials and fuels. A small agricultural sector is highly subsidized and protected, with crop yields among the highest in the world. While self-sufficient in rice production, Japan imports about 60% of its food on a caloric basis. For three decades, overall real economic growth had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the after effects of inefficient investment and an asset price bubble in the late 1980s that required a protracted period of time for firms to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession three times since 2008. A sharp downturn in business investment and global demand for Japan's exports in late 2008 pushed Japan into recession. Government stimulus spending helped the economy recover in late 2009 and 2010, but the economy contracted again in 2011 as the massive 9.0 magnitude earthquake and the ensuing tsunami in March disrupted manufacturing. The economy has largely recovered in the two years since the disaster, but reconstruction in the Tohoku region has been uneven. Prime Minister Shinzo ABE has declared the economy his government's top priority; he has overturned his predecessor's plan to permanently close nuclear power plants and is pursuing an economic revitalization agenda of fiscal stimulus, monetary easing, and structural reform. Japan joined the Trans Pacific Partnership negotiations in 2013, a pact that would open Japan's economy to increased foreign competition and create new export opportunities for Japanese businesses. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, Japan in 2013 stood as the fourth-largest economy in the world after second-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. The new government will continue a longstanding debate on restructuring the economy and reining in Japan's huge government debt, which is exceeding 230% of GDP. To help raise government revenue and reduce public debt, Japan decided in 2013 to gradually increase the consumption tax to a total of 10% by the year 2015. Japan is making progress on ending deflation due to a weaker yen and higher energy costs, but reliance on exports to drive growth and an aging, shrinking population pose other major long-term challenges for the economy.

 

Source : CIA

COMPANY NAME & ADDRESS

 

KOWA COMPANY LTD

 

REGD NAME:   Kowa KK

MAIN OFFICE:  3-6-29 Nishiki Nakaku Nagoya 460-8625 JAPAN

                                    Tel: 052-963-3033

 

                        *.. The is its Tokyo Head Office

                                               

URL:                 http://www.kowa.co.jp

E-Mail address: info@kowa.co.jp

 

 

ACTIVITIES

 

Mfg of pharmaceuticals, medical equipment;

Import, export, wholesale of textiles, apparel, machinery, chemicals, other

 

 

BRANCHES   

 

Tokyo, Osaka, Sapporo, Sendai, Yokohama, Okayama, Fukuoka, etc. (Tot 23)

 

 

OVERSEAS

 

USA (4), Chile, Europe (5), Asia/Pacific (3) (--affiliates)

 

 

FACTORIES  

 

Chofu, Fuji, Gamagori, Nagoya, Hamamatsu, Mooka

 

 

OFFICERS

 

YOSHIHIRO MIWA, PRES          Torao Yamamoto, v pres                      

Koichi Shiraishi, s/mgn dir         Koji Yamashita, s/mgn dir

Tanio Nohara, mgn dir               Toshio Inagi, mgn dir

 

Yen Amount:     In million Yen, unless otherwise stated

 

SUMMARY    

 

FINANCES        FAIR                             A/SALES          Yen 189,681 M

PAYMENTSNO COMPLAINTS    CAPITAL           Yen 3,840 M

TREND SLOW                           WORTH            Yen 109,317 M

STARTED         1939                             EMPLOYES      5,819

 

 

COMMENT    

 

MFR OF PHARMACEUTICALS; IMPORT, EXPORT AND WHOLESALE OF TEXTILES, MACHINERY, OTHERS.

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

                       

MAX CREDIT LIMIT: YEN 4,306.7 MILLION, 30 DAYS NORMAL TERMS

 

 

HIGHLIGHTS

           

The subject company was established on the basis of mfg division separated from Kowa Spinning Co, founded in 1912, Nagoya.  The subject has two major operations: Mfg Division: pharmaceuticals, medical equipment, electronic devices, optical equipment, broadcasting devices; Trading Division: import, export, wholesale of textiles, apparel, machinery, building materials, chemicals, consumer goods, other.  This is a well-known mfr of digestive medicines, cholesterol-lowering agents, hypertensive agents.  Also handles health-care foods.  Group consists of about 70 firms centering in 4 core firms: Kowa Spinning Co Ltd, Kowa Co Ltd, Kowa Pharmaceutical Co Ltd, and Kowa Shinyaku Co Ltd.  In Oct 2006 acquired Nikken Chemical Co Ltd, mfr of pharmaceuticals, to make it a consolidated subsidiary.  In Jul 2007, transferred R&D & mfg divisions from Kowa Pharmaceutical Co Ltd in order to streamline group operations.  Kowa Pharmaceutical is now engaged in marketing and wholesaling businesses.  In Sept 2008 acquired ProEthic Pharmaceutical Inc, USA, and renamed it as Kowa Pharmaceutical America Inc to make it a consolidated subsidiary.

 

Overseas affiliates (pharmaceuticals): Kowa Pharmaceutical Europe Co Ltd, Kowa Research Europe Ltd (--UK); Kowa Research Institute Inc, Kowa Pharmaceutical America Inc (--USA); Kowa Europe GmbH, La Esperanza Delaware Corp; Kowa Asia Ltd; Easiatic Investment Ltd, other

 

 

FINANCIAL INFORMATION

           

The sales volume for Mar/2014 fiscal term amounted to Yen 189,681 million, a 14% down from Yen 220,321 million in the previous term.  The recurring profit was posted at Yen 2,679 million and the net profit at Yen 1,401 million, respectively, compared with Yen 2,536 million recurring profit and Yen 1,550 million net profit, respectively, a year ago

 

For the current term ending Mar 2015 the recurring profit is projected at Yen 2,700 million and the net profit at Yen 1,500 million, respectively, on a 5% rise in turnover, to Yen 200,000 million.  Business is seen steadily expanding.  . 

The financial situation is considered FAIR and good for ORDINARY business engagements.  Max credit limit is estimated at Yen 4,306.7 million, on 30 days normal terms. 

 

 

REGISTRATION

 

Date Registered:                                   Nov 1939

Regd No.:                                             1800-01-035811 (Nagoya-Nakaku)

Legal Status:                            Limited Company (Kabushiki Kaisha)

Authorized:                              96.3 million shares

Issued:                                     37,770,000 shares

Sum:                                        Yen 3,840 million

Major shareholders (%):                       Company’s Treasury Stock (18.8), Kowa Spinning (18.7), MUFG (3.9), Mizuho Bank (3.6), other       

No. of shareholders:                             1,122

           

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: This is a trading house with mfg division:

 

(Sales Breakdown by divisions):

 

Manufacturing Division (39%): Ethical products (analgesic drugs, anti-allergic drugs, cardiovascular drugs, dermatological drugs, ophthalmologic drugs; OTC products (dermatological products, gastrointestinal products, respiratory products, topical analgesic products, tonic, quasi-drugs, health foods & drinks; Sporting optics (binoculars, dig scoping, eye pieces, lenses); Medical equipment (automatic perimeters, binocular loops, digital imaging, digital imaging, fundus camera, anterior segment of the eye, tonometers/perimeters); Audio Video (PXID flash memory, hotkey audio player, professional video & broadcasting equipment); fishing gears, others;

Wholesaling Division (45%): Imports, exports and wholesales textiles, textile materials, apparel, machinery, building materials, chemicals, consumer goods;

Other Divisions (14%): Real estate business, hotel operation, insurance brokerage, printing, others.

Overseas sales ratio (36%).

 

Clients: [Pharmaceutical mfrs, wholesalers] Takisada Osaka, Mediceo Paltac Holdings,   Kowa Shinyaku, Kurabo Ind, Suzuken Co, Alfresa Corp, Kowa Pharmaceutical, Toho Pharmaceutical, Adani Global Pte, Gudami International, other.                             

Exports to Europe, USA, Korea, India, Australia, China, other. 

No. of accounts: 3,000

Domestic areas of activities: Nationwide

Suppliers: [Mfrs, wholesalers] Kowa Spinning, Mitsubishi Rayon, Sanrio Co, Nissan Chemical Ind, Teika Pharmaceutical, SQM Japan, Yutaka Sangyo, Gudami International, Nissan Chemical Ind, other.

Payment record: No Complaints

 

Location: Business area in Nagoya.  Office premises at the caption address are owned and maintained satisfactorily.

 

Bank References:

MUFG (Nagoya)

Mizuho Bank (Nagoya)

Relations: Satisfactory

 

 

FINANCES

 

 (In Million Yen)

       Terms Ending:

31/03/2015

31/03/2014

31/03/2013

31/03/2012

Annual Sales

　

200,000

189,681

220,321

292,332

Recur. Profit

　

2,700

2,679

2,536

9,616

Net Profit

　

1,500

1,401

1,550

11,721

Total Assets

　

　

297,567

283,859

259,443

Current Assets

　

　

103,962

104,321

102,975

Current Liabs

　

　

109,550

115,556

111,766

Net Worth

　

　

109,317

109,779

104,328

Capital, Paid-Up

　

　

3,840

3,840

3,840

Div.P.Share(¥)

　

　

18.00

18.00

18.00

<Analytical Data>

　

(%)

(%)

(%)

(%)

    S.Growth Rate

　

5.44

-13.91

-24.63

9.79

    Current Ratio

　

..

94.90

90.28

92.13

    N.Worth Ratio

　

..

36.74

38.67

40.21

    R.Profit/Sales

　

1.35

1.41

1.15

3.29

    N.Profit/Sales

　

0.75

0.74

0.70

4.01

    Return On Equity

　

..

1.28

1.41

11.23

 

Notes: Forecast figures for the 31/03/2015 fiscal term

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.61.81

UK Pound

1

Rs.96.77

Euro

1

Rs.77.09                      

 

INFORMATION DETAILS

 

Analysis Done by :

KAR

 

 

Report Prepared by :

SMN

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.